Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BMP1 | P13497 | 7/20 | 0.36 |
| ▸ | MMP2 | P08253 | 1/20 | 0.36 |
| ▸ | METAP2 | P50579 | 1/20 | 0.35 |
| ▸ | MEN1 | O00255 | 1/20 | 0.34 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.34 |
| ▸ | F7 | P08709 | 1/20 | 0.34 |
| ▸ | PDE4A | P27815 | 1/20 | 0.32 |
| ▸ | PDE4B | Q07343 | 1/20 | 0.32 |
| ▸ | PDE4C | Q08493 | 1/20 | 0.32 |
| ▸ | PDE4D | Q08499 | 1/20 | 0.32 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.32 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.32 |
| ▸ | PPARG | P37231 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5403174 | 1.00 | BMP1 (0.36) | BMP1MMP2METAP2MEN1KMT2A | |
| SCHEMBL6430229 | 0.89 | SMN1; SMN2 (0.34) | BMP1MMP2MEN1KMT2APDE4A | |
| SCHEMBL6430228 | 0.89 | SMN1; SMN2 (0.34) | BMP1MMP2MEN1KMT2APDE4A | |
| SCHEMBL5759687 | 0.88 | BMP1 (0.37) | BMP1MMP2METAP2MEN1KMT2A | |
| SCHEMBL5759691 | 0.88 | BMP1 (0.37) | BMP1MMP2METAP2MEN1KMT2A | |
| SCHEMBL6872894 | 0.79 | BMP1 (0.37) | BMP1MMP2MEN1KMT2APDE4A | |
| SCHEMBL5409828 | 0.78 | BMP1 (0.36) | BMP1MMP2MEN1KMT2APDE4A | |
| SCHEMBL6872622 | 0.78 | SMN1; SMN2 (0.36) | BMP1MMP2MEN1KMT2APDE4A | |
| SCHEMBL6872619 | 0.78 | SMN1; SMN2 (0.36) | BMP1MMP2MEN1KMT2APDE4A | |
| SCHEMBL5416055 | 0.77 | FKBP1A (0.41) | MEN1KMT2ASMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7214694-B2 | 3-ox(adi)azolylpropanohydroxamic acids useful as procollagen C-proteinase inhibitors | PFIZER INC (US) | 2007-05-08 | — | — | US | disclosed |
| US-20040142986-A1 | 3-ox(adi)azolylpropanohydroxamic acids useful as procollagen C-proteinase inhibitors | DATTA USA (GB) | 2004-07-22 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040142986-A1 | 3-ox(adi)azolylpropanohydroxamic acids useful as procollagen C-proteinase inhibitors | ALPI, TIMP3, MMP1 | BMP1 376/4885MMP2 22/4885METAP2 532/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.